Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 21/06/2024 pm IST			5-day change	1st Jan Change
1,806 ^DKK	+0.50%		-1.45%	-16.19%

10/06	Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
04/06	Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	MT

Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 25, 2024.

May 02, 2024 at 08:39 pm IST

From March 18, 2024 to March 31, 2024, the company has repurchased 121,123 shares, representing 0.19% for DKK 250.6 million. With this, the company has completed the repurchase of 121,123 shares, representing 0.19% for DKK 250.6 million under the buyback announced on March 25, 2024.

Latest news about Genmab A/S

Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM	10/06
Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	04/06	MT
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study	03/06	MT
Transcript : Genmab A/S - Special Call	03/06
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin	03/06	CI
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial	03/06	CI
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial	03/06	MT
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma	03/06	CI
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab	01/06	CI
Genmab A/S Reaffirms Financial Guidance for 2024	21/05	CI
Genmab A/S completed the acquisition of ProfoundBio, Inc.	21/05	CI
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'	15/05	MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%	15/05	MT
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress	14/05	CI
GENMAB : A good start to 2024; guidance unchanged	03/05
Genmab Posts Q1 Net Profit Surge; Revenue Jumps	03/05	MT
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance	02/05	MT
Transcript : Genmab A/S, Q1 2024 Earnings Call, May 02, 2024	02/05
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 1, 2021.	02/05	CI
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 25, 2024.	02/05	CI
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	30/04	MT
Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment	30/04	MT
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer	30/04	CI
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug	30/04	DJ

Chart Genmab A/S

Duration

Period

More charts

Company Profile

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 10:38 pm IST

More Strategies

Ratings for Genmab A/S

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,806 DKK

Average target price

2,464 DKK

Spread / Average Target

+36.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENMAB A/S	-16.19%	1.65TCr
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.91%	11TCr
ARGENX SE	+8.24%	2.36TCr
BIONTECH SE	-19.80%	2.04TCr
BEIGENE, LTD.	-13.45%	1.64TCr
WUXI APPTEC CO., LTD.	-44.35%	1.56TCr
SAREPTA THERAPEUTICS, INC.	+66.67%	1.52TCr
NEUROCRINE BIOSCIENCES, INC.	+2.13%	1.35TCr
INSMED INCORPORATED	+119.39%	1.1TCr

Bio Therapeutic Drugs